## TMO: Thermo Fisher Scientific Inc - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -5.0% below STRENGTH zone (4.0-10.0%); PEG 1.95 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-3.2% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($537.55)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 6, Bearish: 0)

**1. KeyBanc upgrades Thermo Fisher Scientific stock rating to Overweight with $750 target**
- Source: Investing.com | 20251208T055050 | Bullish | Relevance: 98%
-  KeyBanc has upgraded Thermo Fisher Scientific (NYSE:TMO) to Overweight with a $750 price target, citing improving macro conditions and strong execution. The firm notes normalizing biopharma spending and above-average growth in key areas like BioProduction and Research & Safety. Thermo Fisher has also recently expanded bioprocessing capabilities in Asia and issued €2.1 billion in senior notes, while Moody's and Morgan Stanley also upgraded the company's ratings.

**2. Jump Financial LLC Purchases 38,298 Shares of Thermo Fisher Scientific Inc. $TMO**
- Source: MarketBeat | 20251207T120928 | Bullish | Relevance: 98%
-  Jump Financial LLC significantly increased its stake in Thermo Fisher Scientific Inc. ($TMO) during Q2 by purchasing an additional 38,298 shares, bringing their total holdings to 110,952 shares valued at $44,987,000. Several other institutional investors also adjusted their positions in the medical research company. Thermo Fisher Scientific recently announced strong quarterly earnings, a significant stock buyback program, and a quarterly dividend of $0.43 per share.

**3. Bollard Group LLC Acquires 62,000 Shares of Thermo Fisher Scientific Inc. $TMO**
- Source: MarketBeat | 20251207T084701 | Somewhat-Bullish | Relevance: 98%
-  Bollard Group LLC significantly increased its stake in Thermo Fisher Scientific Inc., acquiring an additional 62,000 shares, bringing their total to 62,001 shares valued at over $25 million. This makes Thermo Fisher Scientific the 23rd largest position in Bollard Group LLC's portfolio. Other institutional investors have also modified their holdings, while company insiders have sold a substantial number of shares recently.

**4. Natixis Has $23.43 Million Stock Position in Thermo Fisher Scientific Inc. $TMO**
- Source: MarketBeat | 20251209T132304 | Bullish | Relevance: 98%
- Natixis significantly increased its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 127.6% in the second quarter, bringing its holding to 57,783 shares valued at $23.43 million. Other institutional investors also adjusted their positions in the medical research company, which recently reported strong earnings and announced a quarterly dividend of $0.43 per share. Wall Street analysts maintain a "Moderate Buy" rating for TMO, with a consensus price target of $612.95.

**5. Q4 Earnings Estimate for TMO Issued By KeyCorp**
- Source: MarketBeat | 20251209T133338 | Bullish | Relevance: 98%
-  KeyCorp analysts have issued their Q4 2025 earnings per share estimate for Thermo Fisher Scientific (NYSE: TMO) at $6.48, maintaining an "Overweight" rating and a $750.00 price target. This comes alongside other analyst updates, with a consensus "Moderate Buy" rating and an average price target of $612.95 for the company. Thermo Fisher Scientific recently reported Q3 earnings of $5.79 per share, beating consensus estimates, and announced a quarterly dividend and a $5.00 billion share repurchase program.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Goldman Sachs | $685 | $0 | 0% |
| 2025-12-08 | Keybanc | $750 | $0 | 0% |
| 2025-12-02 | Morgan Stanley | $670 | $656 | +2% |
| 2025-12-01 | HSBC | $670 | $550 | +22% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Goldman Sachs | init | Buy |
| 2025-12-08 | Keybanc | up | Overweight |
| 2025-12-02 | Morgan Stanley | main | Overweight |
| 2025-12-01 | HSBC | up | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 6 ($1.76M) |
| Sells | 14 ($41.68M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 38.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 8 / 2 |

**Top Holders:**
- Vanguard Group Inc: 9.0% (+0.2%)
- Blackrock Inc.: 7.9% (+8.4%)
- State Street Corpora: 4.4% (-0.6%)
- JPMORGAN CHASE & CO: 3.9% (+58.9%)
- Morgan Stanley: 3.4% (-1.2%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-3.2% 5d) with bearish MACD, trend may be turning.
2. Heavy insider selling: $42M sold (14 transactions in 90 days).
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.95 elevated, pricing in significant growth expectations. Forward P/E 22.8x stretched relative to 8% growth. Balance sheet: $1.8B free cash flow. Analyst sentiment positive (2 raises, avg +12%). Insider selling cluster ($41.7M in 90 days), potential headwind. Institutional flow bullish (8 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $211.5B |
| Beta | 0.90 |
| 52W Range | $385.46 - $610.97 |
| Short Interest | 1.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.95 |
| Forward P/E | 22.8 |
| Current P/E | 24.8 |
| YoY Growth | 8.4% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from -1.9% to -5.0% (-3.2% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 9.1pp (needs >4.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.17x) but short-term weakness (below SMA20). MACD histogram bearish (-4.20), momentum weakening. RSI neutral at 43.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -5.05% (CS: 17) | Weak |
| RSI_14 | 43.1 | Neutral |
| MACD Histogram | -4.20 | Bearish |
| vs SMA20 | 0.970x | Below |
| vs SMA50 | 1.004x | Above |
| vs SMA200 | 1.170x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $563.07
- **Stop Loss:** $537.55 (4.5% risk)
- **Target:** $588.59 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 11
- **Position Value:** $6,193.77
- **Portfolio %:** 6.19%
- **Risk Dollars:** $300.00
- **Risk Per Trade:** 0.30%
- **Modifiers:** L1 100% | L2 25% | Combined 0.30x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TOXIC (Zone G) | 0.25x |

*NORMAL regime with moderate risk appetite. VIX remains in the mid-range, breadth is moderate, and yield curve is flat but not inverted—indicating standard late-cycle conditions. Upbeat earnings and positive tech momentum are offset by cautious guidance in consumer sectors, suggesting selective positioning is favored.*

### Earnings

**Next:** 2026-01-29 (Est: $6.45)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $5.50 | $5.79 | +5.3% |
| 2025Q2 | $5.23 | $5.36 | +2.5% |
| 2025Q1 | $5.10 | $5.15 | +0.9% |
| 2024Q4 | $5.94 | $6.10 | +2.7% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*